Eli Lilly and Company (NYSE:LLY) is Cypress Capital Group's 3rd Largest Position

Cypress Capital Group cut its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 54,848 shares of the company's stock after selling 1,417 shares during the period. Eli Lilly and Company comprises about 5.5% of Cypress Capital Group's holdings, making the stock its 3rd biggest holding. Cypress Capital Group's holdings in Eli Lilly and Company were worth $48,592,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 87,091.7% during the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock worth $11,041,631,000 after purchasing an additional 12,448,888 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Eli Lilly and Company by 5.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock valued at $3,242,296,000 after acquiring an additional 171,595 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Eli Lilly and Company by 7.3% in the 1st quarter. Janus Henderson Group PLC now owns 3,575,684 shares of the company's stock valued at $2,781,613,000 after acquiring an additional 243,729 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Eli Lilly and Company by 0.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company's stock worth $2,741,832,000 after purchasing an additional 22,392 shares in the last quarter. Finally, American Century Companies Inc. grew its position in shares of Eli Lilly and Company by 5.1% in the second quarter. American Century Companies Inc. now owns 2,069,881 shares of the company's stock valued at $1,874,029,000 after purchasing an additional 100,426 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 3.2 %

Shares of LLY stock opened at $753.41 on Thursday. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The company has a 50 day moving average price of $872.25 and a 200 day moving average price of $869.98. The stock has a market capitalization of $715.23 billion, a P/E ratio of 81.45, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business's revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. Equities research analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company's dividend payout ratio (DPR) is 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an "overweight" rating in a research report on Friday, September 13th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an "outperform" rating and a $1,100.00 price objective for the company. Guggenheim increased their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.